Among other immune-modulating treatments, recombinant human thrombomodulin (rhTM) has anti-inflammatory and anticoagulation activities, and it has been suggested as an adjunct therapy for patients with sepsis, particularly those with sepsis-induced coagulopathy. The gene discussed is THBD; the disease is Sepsis.